BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin and Ozuriftamab Vedotin in Combination with Opdivo® for Treatment of Solid Tumors Pharmaceutical Investing
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer Pharmaceutical Investing
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies Pharmaceutical Investing
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan's 40th Annual Healthcare Conference Pharmaceutical Investing
Merck's KEYTRUDA® Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression Pharmaceutical Investing
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics Pharmaceutical Investing
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases Life Science Investing
Merck to Hold Fourth-Quarter and Full-Year 2021 Sales and Earnings Conference Call on February 3 Life Science Investing
AbbVie Submits Applications for Upadacitinib in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration and European Medicines Agency Pharmaceutical Investing
